Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-18 · accession 0001193125-26-059637 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-19 | 2026-02-18 | CGEM | Fenton Mary Kay | CFO | A - Grant | $0.00 | +68.8K | 130.8K | +111% | $0 |
| D | 2026-02-19 | 2026-02-18 | CGEM | Fenton Mary Kay | CFO | A - Grant | $0.00 | +137.5K | 137.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | A | A | 68,750 | $0.00 | 130,778 | D | — | — | (F1) The shares underlying the restricted stock unit vest on an annual basis over four years. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-18 | A | A | 137,500 | $0.00 | 137,500 | D | $12.44 · — to 2036-02-18 | 137,500 Common Stock | (F2) The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |